Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib in advanced breast cancer with homologous recombination deficiency
KCT0005563Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in breast cancer, sponsored by Pfizer. Started May 2021; status: active, not recruiting.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0005563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005563.